Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma
Terminated
- Conditions
- Glioblastoma
- Registration Number
- NCT03287063
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Brief Summary
Glioblastomas (GBM) demonstrate in vivo genetic and histologic heterogeneity that can be non-invasively identified using imaging phenotypes that identify regionally distinct areas of tumor with genetic alterations that drive tumor resistance pathways. The researchers propose a unique approach to assess initial GBM heterogeneity by performing histological and genomic analysis of biopsies targeted by advanced MRI before treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
- Suspected newly diagnosed or recurrent supratentorial glioblastoma eligible for surgical biopsy and/or resection
- Patients must be 18 years of age or older
- Study-specific informed consent approved for this purpose by the IRB of the University of Michigan
Exclusion Criteria
- Patients unable to undergo MRI
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identify candidate genes with differential expression in therapy-resistant imaging subvolumes At time of surgery
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Michigan
🇺🇸Ann Arbor, Michigan, United States